Related Experiment Video
Updated: Aug 13, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models
Klaus P Hoeflich1, Daniel C Gray, Michael T Eby
1Department of Molecular Biology, Genentech Inc., 1 DNA Way MS224, South San Francisco, CA 94080, USA.
Abstract:
The usual paradigm for developing kinase inhibitors in oncology is to use a high-affinity proof-of-concept inhibitor with acceptable metabolic properties for key target validation experiments. This approach requires substantial medicinal chemistry and can be confounded by drug toxicity and off-target activities of the test molecule. As a better alternative, we have developed inducible short-hairpin RNA xenograft models to examine the in vivo efficacy of inhibiting oncogenic BRAF. Our results show that tumor regression resulting from BRAF suppression is inducible, reversible, and tightly regulated in these models. Analysis of regressing tumors showed the primary mechanism of action for BRAF to be increased tumor cell proliferation and survival. In a metastatic melanoma model, conditional BRAF suppression slowed systemic tumor growth as determined by in vivo bioluminescence imaging. Taken together, gain-of-function BRAF signaling is strongly associated with in vivo tumorigenicity, confirming BRAF as an important target for small-molecule and RNA interference-based therapeutics.
Insights
Inducible BRAF suppression in xenograft models effectively regresses tumors, demonstrating BRAF
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Traditional kinase inhibitor development for oncology relies on high-affinity molecules for target validation.
- This conventional method faces challenges including drug toxicity and off-target effects.
- An alternative approach is needed for robust in vivo target validation.
Purpose of the Study:
- To develop and utilize inducible short-hairpin RNA xenograft models for validating oncogenic BRAF inhibition in vivo.
- To investigate the efficacy and regulatory mechanisms of BRAF suppression in tumor regression.
Main Methods:
- Development of inducible short-hairpin RNA xenograft models.
- In vivo efficacy studies of BRAF suppression.
- Analysis of tumor regression mechanisms using bioluminescence imaging.
Main Results:
- BRAF suppression led to inducible, reversible, and tightly regulated tumor regression.
- BRAF inhibition was found to increase tumor cell proliferation and survival.
- Conditional BRAF suppression slowed systemic tumor growth in a metastatic melanoma model.
Conclusions:
- Gain-of-function BRAF signaling is critical for in vivo tumorigenicity.
- BRAF is a validated therapeutic target for both small-molecule and RNA interference-based treatments.
- Inducible RNA interference models provide a superior alternative for in vivo target validation.
More Related Videos
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Ras Gene
Ras is a superfamily...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

